Sugi Predict

Sugi Predict / Compounds / SCHEMBL906202

SCHEMBL906202

SCHEMBL906202

COc1cc(B(O)O)ccc1OCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 4/20 0.57
▸ RAB9A P51151 4/20 0.57
▸ HPGD P15428 1/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.57
▸ LIPE Q05469 1/20 0.55
▸ ENPP2 Q13822 1/20 0.53
▸ MEN1 O00255 3/20 0.51
▸ KMT2A Q03164 3/20 0.51
▸ CTSV O60911 1/20 0.51
▸ CTSL P07711 1/20 0.51
▸ BCHE P06276 1/20 0.51
▸ APP P05067 3/20 0.50
▸ KDM4E B2RXH2 2/20 0.50
▸ MTNR1A P48039 1/20 0.50
▸ MTNR1B P49286 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ CYP2D6 P10635 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ BLM P54132 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29956215 1.00 NPC1 (0.57) NPC1RAB9AHPGDSMN1; SMN2LIPE
SCHEMBL4329673 0.94 SMPD1 (0.56) NPC1RAB9AHPGDSMN1; SMN2LIPE
SCHEMBL16320521 0.91 LIPE (0.57) NPC1RAB9AHPGDSMN1; SMN2LIPE
SCHEMBL1516704 0.87 ENPP2 (0.59) NPC1RAB9ASMN1; SMN2ENPP2MEN1
SCHEMBL29951215 0.85 PLK1 (0.53) NPC1RAB9AHPGDSMN1; SMN2ENPP2
SCHEMBL28606699 0.84 LIPE (0.68) NPC1RAB9AHPGDSMN1; SMN2LIPE
SCHEMBL29956153 0.84 LMNA (0.56) NPC1RAB9AENPP2
SCHEMBL129000 0.84 LIPE (0.54) NPC1RAB9AHPGDSMN1; SMN2LIPE
SCHEMBL5623275 0.83 LIPE (0.53) NPC1RAB9AHPGDSMN1; SMN2LIPE
SCHEMBL1163386 0.83 LIPE (0.57) SMN1; SMN2LIPEENPP2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025002363-A1 GEL ELECTROLYTE ELECTRODE, SEPARATOR, LITHIUM ION BATTERY, AND PREPARATION METHODS THEREFOR 深圳市固易能科技有限责任公司 2025-01-02 — — WO disclosed
CN-118841633-A Gel electrolyte electrode, separator, lithium ion battery and manufacturing methods thereof 深圳市固易能科技有限责任公司 2024-10-25 — — CN disclosed
US-20240216357-A1 POLYCYCLIC COMPOUND AND APPLICATION THEREOF SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) 2024-07-04 — — US disclosed
US-20240216357-A1 POLYCYCLIC COMPOUND AND APPLICATION THEREOF SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) 2024-07-04 — — US disclosed
CN-117062813-A Polycyclic compound and application thereof 四川汇宇制药股份有限公司 2023-11-14 — — CN disclosed
US-20220388999-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS BIAL PORTELA & CA SA (PT) 2022-12-08 — — US disclosed
US-11414599-B2 Polymerizable compounds and the use thereof in liquid-crystal displays MERCK PATENT GMBH (DE) 2022-08-16 — — US disclosed
US-11225606-B2 Polymerizable compounds and the use thereof in liquid-crystal displays MERCK PATENT GMBH (DE) 2022-01-18 — — US disclosed
US-20200248078-A1 POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS MERCK PATENT GMBH (DE) 2020-08-06 — — US disclosed
CN-108698973-B Polymerizable compound and liquid crystal composition using same DIC株式会社 2020-07-03 — — CN disclosed
US-20090054437-A1 Nitrocatechol Derivatives as Comt Inhibitors PORTELA & CA., S.A. (PT) 2009-02-26 — — US disclosed
EP-2027091-A1 NEW PHARMACEUTICAL COMPOUNDS BIAL - Portela & Ca., S.A. (PT) 2009-02-25 — — EP disclosed
US-20080194583-A1 Tubulin Inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD 2008-08-14 — — US disclosed
EP-1907382-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS Portela & C.A. S.A (PT) 2008-04-09 — — EP disclosed
EP-1689715-A4 TUBULIN INHIBITORS CYTOPIA RES PTY LTD (AU) 2008-01-23 — — EP disclosed
WO-2007117165-A1 NEW PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & CA, S.A. (PT) 2007-10-18 — — WO disclosed
WO-2007013830-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS PORTELA & CA. S.A. (PT) 2007-02-01 — — WO disclosed
CN-1890218-A Tubulin inhibitors CYTOPIA RES PTY LTD (AU) 2007-01-03 — — CN disclosed
EP-1689715-A1 TUBULIN INHIBITORS Cytopia Research Pty Ltd (AU) 2006-08-16 — — EP disclosed
WO-2005054199-A1 TUBULIN INHIBITORS CYTOPIA RESEARCH PTY LTD (AU) 2005-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11225606-B2 Polymerizable compounds and the use thereof in liquid-crystal displays VCL, PLEC, EML4 NPC1 3628/4885RAB9A 1274/4885HPGD 3890/4885
US-20080194583-A1 Tubulin Inhibitors TUBB1, TUBB3, TUBA1C NPC1 1191/4885RAB9A 885/4885HPGD 3653/4885
US-20220388999-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 NPC1 504/4885RAB9A 2264/4885HPGD 253/4885
US-20090054437-A1 Nitrocatechol Derivatives as Comt Inhibitors COMT, PNMT, OPRK1 NPC1 470/4885RAB9A 2248/4885HPGD 246/4885
US-11414599-B2 Polymerizable compounds and the use thereof in liquid-crystal displays VCL, PLEC, EML4 NPC1 3628/4885RAB9A 1274/4885HPGD 3890/4885
US-20240216357-A1 POLYCYCLIC COMPOUND AND APPLICATION THEREOF KDM1A, TET1, KDM3A NPC1 1373/4885RAB9A 4231/4885HPGD 2127/4885
US-20200248078-A1 POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS VCL, PLEC, EML4 NPC1 3628/4885RAB9A 1274/4885HPGD 3890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.